These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 33741332)

  • 1. Susceptibility of multiple myeloma to B-cell lymphoma 2 family inhibitors.
    Lernoux M; Schnekenburger M; Dicato M; Diederich M
    Biochem Pharmacol; 2021 Jun; 188():114526. PubMed ID: 33741332
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bcl-2 antisense therapy in B-cell malignancies.
    Chanan-Khan A
    Blood Rev; 2005 Jul; 19(4):213-21. PubMed ID: 15784299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting Bcl-2 for the treatment of multiple myeloma.
    Touzeau C; Maciag P; Amiot M; Moreau P
    Leukemia; 2018 Sep; 32(9):1899-1907. PubMed ID: 30076373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting BCL-2 in B-cell malignancies and overcoming therapeutic resistance.
    Kapoor I; Bodo J; Hill BT; Hsi ED; Almasan A
    Cell Death Dis; 2020 Nov; 11(11):941. PubMed ID: 33139702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells.
    Chauhan D; Li G; Podar K; Hideshima T; Neri P; He D; Mitsiades N; Richardson P; Chang Y; Schindler J; Carver B; Anderson KC
    Cancer Res; 2005 Sep; 65(18):8350-8. PubMed ID: 16166312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dissecting the multiple myeloma-bone microenvironment reveals new therapeutic opportunities.
    Shay G; Hazlehurst L; Lynch CC
    J Mol Med (Berl); 2016 Jan; 94(1):21-35. PubMed ID: 26423531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BCL-X expression in multiple myeloma: possible indicator of chemoresistance.
    Tu Y; Renner S; Xu F; Fleishman A; Taylor J; Weisz J; Vescio R; Rettig M; Berenson J; Krajewski S; Reed JC; Lichtenstein A
    Cancer Res; 1998 Jan; 58(2):256-62. PubMed ID: 9443402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histone deacetylase inhibition in combination with MEK or BCL-2 inhibition in multiple myeloma.
    Ramakrishnan VG; Miller KC; Macon EP; Kimlinger TK; Haug J; Kumar S; Gonsalves WI; Rajkumar SV; Kumar SK
    Haematologica; 2019 Oct; 104(10):2061-2074. PubMed ID: 30846494
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acquired resistance to rituximab is associated with chemotherapy resistance resulting from decreased Bax and Bak expression.
    Olejniczak SH; Hernandez-Ilizaliturri FJ; Clements JL; Czuczman MS
    Clin Cancer Res; 2008 Mar; 14(5):1550-60. PubMed ID: 18316580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Bcl-2 inhibitor ABT-263 enhances the response of multiple chemotherapeutic regimens in hematologic tumors in vivo.
    Ackler S; Mitten MJ; Foster K; Oleksijew A; Refici M; Tahir SK; Xiao Y; Tse C; Frost DJ; Fesik SW; Rosenberg SH; Elmore SW; Shoemaker AR
    Cancer Chemother Pharmacol; 2010 Oct; 66(5):869-80. PubMed ID: 20099064
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BCL-2 Inhibitors, Present and Future.
    Ryan CE; Davids MS
    Cancer J; 2019; 25(6):401-409. PubMed ID: 31764121
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models.
    Punnoose EA; Leverson JD; Peale F; Boghaert ER; Belmont LD; Tan N; Young A; Mitten M; Ingalla E; Darbonne WC; Oleksijew A; Tapang P; Yue P; Oeh J; Lee L; Maiga S; Fairbrother WJ; Amiot M; Souers AJ; Sampath D
    Mol Cancer Ther; 2016 May; 15(5):1132-44. PubMed ID: 26939706
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone marrow microenvironment-derived signals induce Mcl-1 dependence in multiple myeloma.
    Gupta VA; Matulis SM; Conage-Pough JE; Nooka AK; Kaufman JL; Lonial S; Boise LH
    Blood; 2017 Apr; 129(14):1969-1979. PubMed ID: 28151428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
    Chung C
    Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting BCL-2 in B-cell lymphomas.
    Davids MS
    Blood; 2017 Aug; 130(9):1081-1088. PubMed ID: 28724540
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel therapeutic strategies for multiple myeloma.
    Mimura N; Hideshima T; Anderson KC
    Exp Hematol; 2015 Aug; 43(8):732-41. PubMed ID: 26118499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemosensitization of myeloma plasma cells by an antisense-mediated downregulation of Bcl-2 protein.
    van de Donk NW; Kamphuis MM; van Dijk M; Borst HP; Bloem AC; Lokhorst HM
    Leukemia; 2003 Jan; 17(1):211-9. PubMed ID: 12529680
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The imbalance between Bim and Mcl-1 expression controls the survival of human myeloma cells.
    Gomez-Bougie P; Bataille R; Amiot M
    Eur J Immunol; 2004 Nov; 34(11):3156-64. PubMed ID: 15459900
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug resistance in multiple myeloma: novel therapeutic targets within the malignant clone.
    Pilarski LM; Mant MJ; Belch AR
    Leuk Lymphoma; 1999 Jan; 32(3-4):199-210. PubMed ID: 10037018
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma.
    Chiron D; Dousset C; Brosseau C; Touzeau C; Maïga S; Moreau P; Pellat-Deceunynck C; Le Gouill S; Amiot M
    Oncotarget; 2015 Apr; 6(11):8750-9. PubMed ID: 25797245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.